Alpha Tau Medical™
Alpha Tau Medical™ was founded in 2016 by CEO Uzi Sofer to develop and commercialize the Alpha DaRT™ (Diffusing Alpha-emitters Radiation Therapy), invented by Professors Itzhak Kelson and Yona Keisari from Tel Aviv University. Alpha Tau’s goal is to bring this innovative alpha radiation technology to cancer patients around the world.
In 2017, Alpha Tau started with its first-in-human study of locally advanced and recurrent SCC cancers of the skin and head and neck, the results of which were subsequently published in the prestigious International Journal of Radiation Oncology | Biology | Physics. The study and its results were received with great enthusiasm, as can be seen, for example, in an editorial that was published in the same journal.
Following these initial encouraging results, Alpha Tau substantially expanded its clinical evaluations in later trials to a much wider patient population.
The supportive data from these first trials also led to the FDA granting Breakthrough Device Designation to the Alpha DaRT for the treatment of patients with SCC of the skin or oral cavity without curative standard of care. Later on, Alpha Tau also received FDA's Breakthrough Device Designation for the Treatment of Recurrent GBM (glioblastoma multiforme).
Today, in partnership with a number of esteemed medical and educational institutions worldwide, Alpha Tau has commenced several clinical and pre-clinical studies which are presently ongoing, and is also currently evaluating other potential uses of the Alpha DaRT technology for indications such as breast, pancreas, lung, GBM and prostate cancers, as well as other applications such as combinations with immunotherapies.
We believe the Alpha DaRT has the potential to revolutionize the treatment of nearly all solid tumors, and we aim to provide a new option for patients with the following types of cancers:
Localized and Unresectable - refractory or recurrent tumors previously treated with surgery and/or conventional radiation therapy, and tumors that can’t be operated on due to their location near sensitive organs, or difficulty to access, or because patients cannot tolerate surgery. For example, SCC of the skin, head & neck, or prostate.
Cancer with no effective existing treatments. Tumor types with high unmet need, limited treatment options and generally poor prognosis, such as pancreatic adenocarcinoma and glioblastoma.
Metastatic. By combining our Alpha DaRT technology with systemic therapies, such as checkpoint inhibitors, we seek to boost the Alpha DaRT’s potentially immunogenic activity and trigger an immune response to detect and destroy metastatic cancers throughout the body.
“Humanity will draw more good than evil from new discoveries.” -- Marie Curie
The Alpha Tau Team is inspired by Marie Curie who discovered Radium in 1898. Sharing the value and eagerness to serve humanity, the company believes that only through rigorous research and strategic business collaborations can the full therapeutic potential of radium for treating cancer be reached.